The authors wish to sincerely thank all the FiPP staff and families participating in the study, and the many other people who contributed to the study including:

Amanda O’Brien, Kathryn Bright, Samantha Colquhoun, Amy Bin Chen, Timothy Gemetzis, Amy Auge, Katherine Gilbert, Evan Willis, Philip Greenwood, Beth Temple, Vanessa Johnston, Loretta Thorn, Porter Anderson, Brian Greenwood, George Siber, David Klein, Elizabeth Horigan, and Farukh Khambaty. The authors wish to thank the DSMB members. Pneumovax™ was kindly donated by CSL Biotherapies, Australia. The co-administered Tritanrix™-HepB™ and Hiberix™ vaccines were kindly donated by GlaxoSmithKline. Conflicts of interest: MLT has been a consultant/advisor for Wyeth. The other authors declared no conflicts of interest. Funding: Funding was provided by the U.S. NIAID and the Australian National Health and Medical Research Council. Trials SCR7 ic50 registration: Clinical Trial Registry, National Library of Medicine, USA. Clinical trial

number: NCT00170612. “
“In the UK, preschoolers aged 3–5 years old are offered a second dose of measles, mumps and rubella (MMR) vaccine, and a booster against diphtheria, tetanus, pertussis and polio (dTaP/IPV or DTaP/IPV). The latest immunisation statistics for England indicate that uptake of these vaccinations continues to be lower than that of the primary course [1]. Despite this, only a limited number of studies [2], [3], [4] and [5] have examined parents’ views about preschool immunisation and little is known about the beliefs that might best predict parents’ vaccination decisions. Semi-structured

see more interviews with parents of young infants [3] and parents of preschoolers [4] have identified uncertainty about the need for vaccinations at preschool age. Compared with primary immunisation, the parents of preschoolers reported receiving no information prior to their invitation to attend and had little or no contact with healthcare professionals at their general practice. Earlier interviews also found that parents typically reported receiving no information about the second MMR prior to immunisation and were unable to recall advice given when they had taken their child Edoxaban for the first dose aged 13–18 months [6]. In support, quantitative research has found that receipt of satisfactory information was significantly associated with MMR and pertussis immunisation among mothers of children aged 3 months to 6 years old in Italy [2]. In Australia, a study looking at interventions to increase uptake in school entrants found that the main reasons given for incomplete immunisation were lack of awareness that boosters were required and parental indifference, such as forgetting to attend [7]. In both studies, minor illness delayed parents from immunising on time. Another body of evidence has used psychological theory to examine parents’ intentions to immunise.